Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/009692TRIPARTITE SYSTEMS FOR PROTEIN DIMERIZATION AND METHODS OF USE
WO 21.01.2021
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
Appl.No PCT/IB2020/056657 Applicant MEDIMMUNE LIMITED Inventor BAMBER, Lisa
The disclosure provides compositions and methods that make use of a target protein that is capable of binding to a small molecule in order to form a complex, and a binding member that specifically binds to the complex, wherein the target protein is derived from a non-human protein and the small molecule is an inhibitor of the non-human protein. The non-human protein may be derived from a viral, bacterial, fungal or protozoal protein. These compositions and methods permit the controlled interaction of polypeptides that are individually fused to the target protein and binding member, respectively, and can be used to control the activity of dimerization-inducible proteins such as split transcription factors and split chimeric antigen receptors through the addition of the small molecule. The disclosure provides expression vectors, binding members, dimerization-inducible proteins, nucleic acids, cells, viral particles, kits, systems and methods that involve these components.
2.WO/2021/010712ANTI-TAU ANTIBODY AND USE OF SAME
WO 21.01.2021
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/KR2020/009207 Applicant ADEL, INC. Inventor YOON, Seung-Yong
The present invention relates to an anti-tau antibody specifically binding to a tau protein, and a use of same. The anti-tau antibody according to the present invention specifically binds to a tau protein in which lysine at position 280 is acetylated and can suppress abnormal aggregation of tau proteins. In addition, the anti-tau antibody according to the present invention, when administered to an animal model of induced dementia, can improve locomotor activity and cognitive ability in the animal model. Therefore, the anti-tau antibody according to the present invention may be utilized in the prevention or treatment of neurodegenerative diseases.
3.WO/2021/011417CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT
WO 21.01.2021
Int.Class C07K 16/44
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
44against material not provided for elsewhere
Appl.No PCT/US2020/041710 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor CRAIK, Charles S.
The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.
4.WO/2021/011377METHODS OF ENHANCING IMMUNOGENICITY OF CANCERS
WO 21.01.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/041603 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor BERTOZZI, Carolyn
Provided are methods of enhancing immunogenicity of cancers. In certain aspects, the methods include administering an effective amount of a sialic acid modulator to an individual identified as having a cancer comprising dysregulated Myc. According to some aspects, the methods include administering an effective amount of a disialyl-T modulator to an individual identified as having a cancer comprising cell surface expression of disialyl-T. In certain aspects, the methods include administering an effective amount of an agent to an individual identified as having a cancer comprising cell surface expression of a glycoprotein comprising an O-glycosylated mucin-like domain, where the agent modulates the glycoprotein. Also provided are methods of assessing whether a cancer of an individual comprises dysregulated Myc.
5.WO/2021/009081BINDING AGENTS AND USES THEREOF
WO 21.01.2021
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/EP2020/069667 Applicant JANSSEN PHARMACEUTICA NV Inventor LAMKANFI, Mohamed
The present invention relates to inhibitors that bind to gasdermin D and inhibit gasdermin D-mediated cell death and inflammation. The inhibitors can be proteinaceous, for example antigen binding proteins or non-proteinaceous, such as aptamers. It is disclosed an antibody that binds to the peptide of SEQ ID NO: 9: KREGSGRFSLPGATC. In one embodiment the inhibitor binds to gasdermin D and inhibits its association with lipids, such as wherein the inhibitor binds to gasdermin D and neutralizes the association of gasdermin D with lipids, optionally wherein the inhibitor binds to gasdermin D and inhibits its association with phosphatidyl inositol 4-phosphate and/or phosphatidyl inositol 4, 5-bisphosphate, such as wherein the inhibitor binds to gasdermin D and neutralizes the association of gasdermin D with phosphatidylinositol 4-phosphate and/or phosphatidyl inositol 4, 5-bisphosphate.
6.WO/2021/010326ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREFOR
WO 21.01.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2020/027043 Applicant CHUGAI SEIYAKU KABUSHIKI KAISHA Inventor KAMIKAWAJI, Shogo
The present invention provides an antibody that makes it possible to distinguish between wild FGFR3 and S249C mutation-type FGFR3. In addition, an antigen-binding molecule that makes it possible to selectively damage tumor cells expressing S249C mutation-type FGFR3 was built using the antibody.
7.WO/2021/011496IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
WO 21.01.2021
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
Appl.No PCT/US2020/041844 Applicant OREGON HEALTH & SCIENCE UNIVERSITY Inventor YANTASEE, Wassana
Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.
8.WO/2021/011826PROCESS OF MAKING MEMBRANE LIPID COATED NANOPARTICLES
WO 21.01.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2020/042420 Applicant COASTAR THERAPEUTICS INC. Inventor CHUNG, Eddie, Yocon
Disclosed is a process of making a nanoparticle comprising an inner core comprising a virus and an outer surface comprising a cellular membrane derived from a cell via extrusion.
9.WO/2021/009020EXCIPIENT FOR BIOTHERAPEUTICS
WO 21.01.2021
Int.Class A61K 9/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
08Solutions
Appl.No PCT/EP2020/069494 Applicant LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN Inventor WINTER, Gerhard
The present invention relates to excipients for stabilizing active agents, in particular peptides, polypeptides, nucleic acids, viruses, virus-like particles, proton pump inhibitors and antibiotics. The excipient reduces aggregate and/or particle formation in preparations comprising said agents. The excipient is a diamide of a dicarboxylic acid comprising at least one N-H amido group, at least one unsubstituted or substituted N-hydroxyethylamido group and/or at least one unsubstituted N-hydroxymethylamido group. In particular, the excipient is N,N,N',N'-tetrakis-(2-hydroxyethyl) adipinic acid amide.
10.WO/2021/009740COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUBERCULOSIS
WO 21.01.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/IL2019/050801 Applicant RAMOT AT TEL-AVIV UNIVERSITY LTD. Inventor FREUND, Natalia
A human antibody comprising an antigen binding domain which binds Pst S1 of Mycobacterium tuberculosis (TB) for use in preventing or treating TB infection in a subject in need thereof is provided. Also provided are vaccine compositions and conjugates of such antibodies.